News & Updates

Smartphone app fails to boost MVPA in diabetics
Smartphone app fails to boost MVPA in diabetics
06 Oct 2022 byTristan Manalac

Among patients with type 2 diabetes (T2D), use of the smartphone-based app InterWalk does not improve objective measures of moderate-to-vigorous physical activity (MVPA), according to a study.

Smartphone app fails to boost MVPA in diabetics
06 Oct 2022
Poor glycaemic control tied to death risk in T2D patients with CKD
Poor glycaemic control tied to death risk in T2D patients with CKD
04 Oct 2022

Poorly controlled glycosylated haemoglobin (HbA1c) levels appear to aggravate the risk of mortality in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD), a recent study has found. Glycaemic control is not associated with progression to end-stage kidney disease (ESKD).

Poor glycaemic control tied to death risk in T2D patients with CKD
04 Oct 2022
Use of RAS inhibitors associated with lower cancer risk in T2D
Use of RAS inhibitors associated with lower cancer risk in T2D
03 Oct 2022 byNatalia Reoutova

A real-world study of over 250,000 type 2 diabetes (T2D) patients from Hong Kong has found that use of renin-angiotensin-system inhibitors (RASIs) is independently associated with reduced risk of cancer, including diabetes-related cancers and cancer-specific mortality in diabetes.

Use of RAS inhibitors associated with lower cancer risk in T2D
03 Oct 2022